Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.

Publication

Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.

Journal Paper/Review - Aug 28, 2024

Hilser Thomas, Darr Christopher, Niegisch Günter, Schnabel Marco Julius, Foller Susan, Häuser Lorine, Zschäbitz Stefanie, Lewerich Jonas, Ivanyi Philipp, Schlack Katrin, Paffenholz Pia, Daetwyler Eveline, Niedersüß-Beke Dora, Grünwald Viktor

Citation

Hilser T, Darr C, Niegisch G, Schnabel M, Foller S, Häuser L, Zschäbitz S, Lewerich J, Ivanyi P, Schlack K, Paffenholz P, Daetwyler E, Niedersüß-Beke D, Grünwald V. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project. Cancers (Basel) 2024; 16

Type

Journal Paper/Review (English)

Journal

Cancers (Basel) 2024; 16

Publication Date

Aug 28, 2024

Issn Print

2072-6694

Brief description/objective

Combinations of immune-checkpoint inhibitors (ICIs) are the standard of care (SOC) for treatment-naive metastatic renal cell carcinoma (mRCC) patients. In this multicenter study, we evaluated the RW safety and efficacy of cabozantinib plus nivolumab in mRCC patients.